Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Methotrexate + infliximab vs infliximab

Adverse events (Schröder 2006) · adult patients with refractory Crohn's disease

It is very uncertain whether methotrexate + infliximab changes adverse events (Schröder 2006) compared with infliximab alone (very low certainty).

1 finding from 1 review

Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 1.02 [0.51, 2.05]
1 study · 19 participants
Very low

Methotrexate + infliximab vs infliximab

Serious adverse events (Schröder 2006) · adult patients with refractory Crohn's disease

It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).

1 finding from 1 review

Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 0.25 [0.01, 5.45]
1 study · 19 participants
Very low